Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Hepatol. Jan 27, 2018; 10(1): 51-61
Published online Jan 27, 2018. doi: 10.4254/wjh.v10.i1.51
Table 5 Univariate and multivariate Cox regression analyses of factors associated with overall survival (n = 545)
Univariate
Multivariate
HR95%CIP valueHR95%CIP value
Patient related factors
Age0.990.98-1.010.360
Gender0.820.60-1.100.180
Etiology of liver disease
Hepatitis CReference--Reference--
Hepatitis B1.280.98-1.660.0740.980.74-1.300.900
Other (non-viral)1.411.002-1.990.0491.120.78-1.600.540
Stage of liver disease
Normal or precirrhotic liverReference--Reference--
Child-Pugh A1.520.99-2.300.0511.290.84-1.990.250
Child-Pugh B3.162.04-4.88< 0.0011.811.13-2.890.013
Child-Pugh C10.466.57-16.66< 0.0015.353.24-8.83< 0.001
Tumor related factors
Total tumor diameter ≥ 5 cm3.072.40-3.93< 0.0011.741.30-2.33< 0.001
Multinodular or diffuse-infiltrative2.021.61-2.53< 0.0011.230.95-1.590.120
Extrahepatic metastasis2.531.63-3.93< 0.0012.171.37-3.450.001
Vascular invasion3.482.42-5.01< 0.0012.741.84-4.06< 0.001
AFP level > 200 ng/mL2.592.07-3.23< 0.0012.191.72-2.80< 0.001
Treatment modalities vs no treatment
Surgical treatments (OLT, hepatic resection)0.070.04-0.13< 0.0010.120.06-0.24< 0.001
TACE0.240.19-0.31< 0.0010.380.28-0.51< 0.001
Yttrium-90 adioembolization0.370.19-0.720.0030.360.18-0.740.005
RFA0.120.04-0.38< 0.0010.180.05-0.570.004
Ethanol/acetic acid ablation0.600.22-1.630.3180.790.28-2.220.660
Sorafenib0.510.25-1.040.0630.520.25-1.100.088